<?xml version='1.0' encoding='utf-8'?>
<document id="27009433"><sentence text="Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method." /><sentence text="Cytochrome P450 (CYP) activity can be assessed using a 'cocktail' phenotyping approach" /><sentence text=" Recently, we have developed a cocktail (Geneva cocktail) which combines the use of low-dose probes with a low-invasiveness dried blood spots (DBS) sampling technique and a single analytical method for the phenotyping of six major CYP isoforms" /><sentence text=" We have previously demonstrated that modulation of CYP activity after pre-treatment with CYP inhibitors/inducer could be reliably predicted using Geneva cocktail" /><sentence text=" To further validate this cocktail, in this study, we have verified whether probe drugs contained in the latter cause mutual drug-drug interactions" /><sentence text=" In a randomized, four-way, Latin-square crossover study, 30 healthy volunteers received low-dose caffeine, flurbiprofen, omeprazole, dextromethorphan and midazolam (a previously validated combination with no mutual drug-drug interactions); fexofenadine alone; bupropion alone; or all seven drugs simultaneously (Geneva cocktail)"><entity charOffset="98-106" id="DDI-PubMed.27009433.s6.e0" text="caffeine" /><entity charOffset="108-120" id="DDI-PubMed.27009433.s6.e1" text="flurbiprofen" /><entity charOffset="122-132" id="DDI-PubMed.27009433.s6.e2" text="omeprazole" /><entity charOffset="134-150" id="DDI-PubMed.27009433.s6.e3" text="dextromethorphan" /><entity charOffset="155-164" id="DDI-PubMed.27009433.s6.e4" text="midazolam" /><entity charOffset="241-253" id="DDI-PubMed.27009433.s6.e5" text="fexofenadine" /><entity charOffset="261-270" id="DDI-PubMed.27009433.s6.e6" text="bupropion" /><pair ddi="false" e1="DDI-PubMed.27009433.s6.e0" e2="DDI-PubMed.27009433.s6.e0" /><pair ddi="false" e1="DDI-PubMed.27009433.s6.e0" e2="DDI-PubMed.27009433.s6.e1" /><pair ddi="false" e1="DDI-PubMed.27009433.s6.e0" e2="DDI-PubMed.27009433.s6.e2" /><pair ddi="false" e1="DDI-PubMed.27009433.s6.e0" e2="DDI-PubMed.27009433.s6.e3" /><pair ddi="false" e1="DDI-PubMed.27009433.s6.e0" e2="DDI-PubMed.27009433.s6.e4" /><pair ddi="false" e1="DDI-PubMed.27009433.s6.e0" e2="DDI-PubMed.27009433.s6.e5" /><pair ddi="false" e1="DDI-PubMed.27009433.s6.e0" e2="DDI-PubMed.27009433.s6.e6" /><pair ddi="false" e1="DDI-PubMed.27009433.s6.e1" e2="DDI-PubMed.27009433.s6.e1" /><pair ddi="false" e1="DDI-PubMed.27009433.s6.e1" e2="DDI-PubMed.27009433.s6.e2" /><pair ddi="false" e1="DDI-PubMed.27009433.s6.e1" e2="DDI-PubMed.27009433.s6.e3" /><pair ddi="false" e1="DDI-PubMed.27009433.s6.e1" e2="DDI-PubMed.27009433.s6.e4" /><pair ddi="false" e1="DDI-PubMed.27009433.s6.e1" e2="DDI-PubMed.27009433.s6.e5" /><pair ddi="false" e1="DDI-PubMed.27009433.s6.e1" e2="DDI-PubMed.27009433.s6.e6" /><pair ddi="false" e1="DDI-PubMed.27009433.s6.e2" e2="DDI-PubMed.27009433.s6.e2" /><pair ddi="false" e1="DDI-PubMed.27009433.s6.e2" e2="DDI-PubMed.27009433.s6.e3" /><pair ddi="false" e1="DDI-PubMed.27009433.s6.e2" e2="DDI-PubMed.27009433.s6.e4" /><pair ddi="false" e1="DDI-PubMed.27009433.s6.e2" e2="DDI-PubMed.27009433.s6.e5" /><pair ddi="false" e1="DDI-PubMed.27009433.s6.e2" e2="DDI-PubMed.27009433.s6.e6" /><pair ddi="false" e1="DDI-PubMed.27009433.s6.e3" e2="DDI-PubMed.27009433.s6.e3" /><pair ddi="false" e1="DDI-PubMed.27009433.s6.e3" e2="DDI-PubMed.27009433.s6.e4" /><pair ddi="false" e1="DDI-PubMed.27009433.s6.e3" e2="DDI-PubMed.27009433.s6.e5" /><pair ddi="false" e1="DDI-PubMed.27009433.s6.e3" e2="DDI-PubMed.27009433.s6.e6" /><pair ddi="false" e1="DDI-PubMed.27009433.s6.e4" e2="DDI-PubMed.27009433.s6.e4" /><pair ddi="false" e1="DDI-PubMed.27009433.s6.e4" e2="DDI-PubMed.27009433.s6.e5" /><pair ddi="false" e1="DDI-PubMed.27009433.s6.e4" e2="DDI-PubMed.27009433.s6.e6" /><pair ddi="false" e1="DDI-PubMed.27009433.s6.e5" e2="DDI-PubMed.27009433.s6.e5" /><pair ddi="false" e1="DDI-PubMed.27009433.s6.e5" e2="DDI-PubMed.27009433.s6.e6" /></sentence><sentence text=" Pharmacokinetic profiles of the probe drugs and their metabolites were determined in DBS samples using both conventional micropipette sampling and new microfluidic device allowing for self-sampling" /><sentence text=" The 90% confidence intervals for the geometric mean ratios of AUC metabolite/AUC probe for CYP probes administered alone or within Geneva cocktail fell within the 0" /><sentence text="8-1" /><sentence text="25 bioequivalence range indicating the absence of pharmacokinetic interaction" /><sentence text=" The same result was observed for the chosen phenotyping indices, that is metabolic ratios at 2 hr (CYP1A2, CYP3A) or 3 hr (CYP2B6, CYP2C9, CYP2C19, CYP2D6) post-cocktail administration" /><sentence text=" DBS sampling could successfully be performed using a new microfluidic device" /><sentence text=" In conclusion, Geneva cocktail combined with an innovative DBS sampling device can be used routinely as a test for simultaneous CYP phenotyping" /><sentence text=" " /></document>